The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Vertex Pharmaceuticals

  • VRTX
  • NASDAQ
  • Consumer Products
  • Latest 66.18
  • Currency US$
  • Change -0.74
  • Percent Change -1.106 %
  • Volume 1,204,660
  • Thu Apr 24, 2014 04:00 PM EDT NASDAQ data delayed 15 minutes.
  • Open 66.96
  • Previous Close 66.92
  • High 67.49
  • Low 64.05
  • Bidx0 0.0000
  • Askx0 0.0000
  • 52-week High07/19 89.96
  • 52-week Low11/12 58.06
  • Beta 0.19
  • Market Cap 15,470.24M
  • EPS -2.04
  • P/E
  • Forward P/E 95.91
  • PEG
  • Annual Dividend 0.0000
  • Yield
Globe Investor - GIT Upsells
It's never been a better time to get Globe Unlimited
Try Globe Unlimited, featuring new Globe Investor Tools,
for a special trial rate. Only 99¢ for your first month.


Are you a Globe Investor Gold subscriber?
You qualify for complimentary access to Globe Unlimited.
Visit: globeandmail.com/globeplusunlimited
Try it today

News

Financials & Calendars

Income Statement

  • Sales $1,211,980,000
  • Earnings $-445,040,000
  • Return on Equity n/a

Cash Flow

  • Cash Flow --
  • Cash $569,290,000
  • Current Ratio 3.99

12 months ended Dec 31, 2013.

Trailing 12 month results shown above.
All data is in U.S. dollars.

Balance Sheet

  • Assets $2,319,040,000
  • Liabilities $962,630,000
  • Liabilities-to-Equity Ratio 0.71

Price Ratios

  • Price to Sales 12.76
  • Price to Book 11.40
  • Price to Cash Flow n/a

Event Calendar

Event Last   Next  
Earnings Jan 29 $-0.57 May 1 $-0.79
Surprises Jan 29 15.79% n/a n/a
Dividends n/a n/a n/a n/a
Splits n/a -- n/a n/a

12 months ended Apr 24, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

Vertex Pharmaceuticals Inc. discovers, develops and markets small molecule drugs that address major unmet medical needs. The company has eight drug candidates in clinical development to treat viral diseases, inflammation, cancer, autoimmune diseases and neurological disorders. Vertex has created its pipeline using a proprietary information-based approach to drug design that integrates multiple technologies in biology, chemistry and biophysics aimed at increasing the speed and success rate of drug discovery. (PRESS RELEASE)

Related Securities
Symbol Type Latest % Chg

Officers

  • Jeffrey M. Leiden Chairman of the Board; Preside
  • Ian F. Smith Executive Vice President and C
  • Company Type: n/a
  • Company Status: n/a
  • Full-time Employees: n/a
  • Incorporation: United States,
    n/a
  • Top 1000 Ranking: Profit: n/a
    Revenue: n/a
    Assets: n/a

Head Office

50 NORTHERN AVENUE
BOSTON, MA
02210

Phone: (617)-341-6393
Fax: (617)-5762109

investorinfo@vrtx.com
www.vrtx.com

Ideas & Discussion

Live Discussion of VRTX on StockTwits